BIOCORP and Diabeloop Announce Co-Growth Settlement in Customized Diabetes Administration


ISSOIRE, France & GRENOBLE, France – (BUSINESS WIRE) – Regulatory News:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME) (Paris: ALCOR), a French company specializing in the design and manufacture of medical devices and connected solutions in the health sector, and Diabeloop, a young company pioneering therapeutic artificial intelligence with Personalized and Automated Solutions for Diabetes Treatment Management, today announce a collaboration agreement. This collaboration aims to combine the expertise of both companies to offer people with diabetes new, simple and personalized treatment options.

Diabeloop has developed Automated Insulin Delivery (AID) systems, including a self-learning algorithm hosted in a dedicated handset and connected to a Continuous Glucose Monitoring (CGM) solution and an insulin pump. The artificial intelligence developed by Diabeloop analyzes glucose data, calculates the correct dose of insulin and delivers it automatically.

For its part, BIOCORP developed and marketed Mallya, an intelligent sensor for insulin injection pens and the first in its class to receive the CE mark (Class IIb). Compatible with all single-use insulin pens, it allows reliable monitoring of the doses selected for injection and provides patients with diabetes with better adherence to their treatment.

Through this agreement and the integration of Mallya into the technological environment of Diabeloop, patients equipped with insulin pens benefit from a unique, user-friendly and personalized solution to improve their daily care and quality of life.

Eric Dessertenne, CEO of BIOCORP, said: “We are very excited to combine our research and development capabilities with the common goal of improving the quality of care for patients with diabetes. The technological platform developed by Diabeloop in the field of insulin pumps replicates that The functioning of the pancreas thanks to AI has real potential in the insulin pen market. Insulin addicts, users of these pens, are indeed looking for digital services that are increasingly rich in information and advice to better manage their insulin intake. ”

Marc Julien, Co-CEO of Diabeloop, added: “We are excited to enter into this agreement with Biocorp, a highly knowledgeable partner. This collaboration opens up new possibilities for people with diabetes who use insulin pens, using Diabeloop’s simple and personalized interoperable technology offer to have their multiple insulin injections every day ”.

The market for single-use insulin pens is valued at more than $ 9 billion in the top 10 markets (US, France, Germany, Italy, Spain, UK, Japan, China, India and Brazil) by 2022 1.


1Global Diabetes Disposable Insulin Pen Market Report: Country Outlook, Analysis, Size, Share and Forecast 2017-2022 – WiseGuyReports


Diabeloops Mission: To relieve people with type 1 diabetes of dozens of therapeutic decisions and to reduce their severe psychological distress. Diabeloop was originally conceived by a medical research project and was launched in 2015 by Dr. Guillaume Charpentier, today’s Chief Medical Officer, and Erik Huneker, who has headed the company together with Marc Julien since 2016. This complementary management team works with experienced partners, CEA, -Leti (a research laboratory) and CERITD (a French research team of diabetologists).

In 2018, the DBLG1® system, Diabeloop’s first medical device for the automated treatment of diabetes, received the CE mark, followed by DBL-hu, its solution for the treatment of highly unstable type 1 diabetes in 2020.

A second funding round of EUR 31 million was completed in November 2019 to accelerate the international commercial rollout of the DBLG1® iController and support an ambitious R&D program.

The company is supported by several investors and industrial groups in the health sector, including CERITD, Aliad, Cemag Invest, Sofimac Innovation, Supernova Invest, Kreaxi, Crédit Agricole, Odyssée Venture, Agiradom and Business Angels.

Today Diabeloop gathers the personality, passion and skills of nearly 100 talented people who work hard to improve the quality of life for every person with Type 1 Diabetes.


BIOCORP is known for its expertise in the development and manufacture of medical devices and delivery systems and today, thanks to Mallya, has achieved a leading position in the market for connected medical devices. This intelligent sensor for insulin injection pens enables reliable monitoring of the injected doses and thus offers better compliance in the treatment of patients with diabetes. Mallya will be on sale from 2020 and will lead BIOCORP’s product portfolio with innovative networked solutions. The company has 70 employees. BIOCORP has been listed on Euronext since July 2015 (FR0012788065 – ALCOR).

More information is available at